查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098971

細胞與基因治療市場－2026-2032年全球市場預測

Cell & Gene Therapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療市場將成長至 713.8 億美元，複合年成長率為 20.39%。

主要市場統計數據
基準年 2025 194.7億美元
預計年份：2026年 229.8億美元
預測年份 2032 713.8億美元
複合年成長率 (%) 20.39%

細胞與基因療法執行摘要：精準醫療正向永續治療模式轉型

細胞和基因療法正在重塑現代醫學，將治療模式從慢性疾病管理轉向基於潛在永續機制的介入。此領域涵蓋自體和異體細胞療法、基因替代、基因轉移、基因編輯、病毒和非病毒載體、體外和細胞內遞送等基礎技術，以及先進的生物製程、療效檢測、冷凍保存和數位化品管系統。在臨床方面，腫瘤學、血液學、罕見遺傳疾病、眼科學、神經病學、免疫學和再生醫學等領域的發展勢頭最為強勁，這些領域的療法旨在解決潛在的生物學因素，而不僅僅是緩解症狀。

細胞和基因治療領域的變革性變化

科學創新、製造技術的成熟、監管知識的累積以及醫療保健系統的調整，共同推動細胞和基因治療領域的變革性轉變。其中一項重大變革是從第一代自體療法轉向更擴充性應用的療法過渡，例如異體細胞平台、新一代免疫細胞技術、體內基因轉移、基因編輯（包括基礎編輯和啟動編輯）、組織靶向載體以及非病毒遞送系統。這些進步旨在降低生產複雜性、提高治療一致性、縮短給藥時間，並使治療不再局限於高度專業化的醫療中心。

人工智慧對細胞和基因治療的累積影響

人工智慧 (AI) 透過改善藥物發現、轉化研究、生產製造、臨床運作和治療後監測等環節的決策，對整個細胞和基因治療價值鏈產生累積影響。在研發早期階段，AI 模型可輔助標靶辨識、載體最佳化、引導 RNA 設計、蛋白質工程、細胞表現型預測和生物標記發現。利用機器學習，可以分析高維度基因組、轉錄組、蛋白質組、影像和單細胞資料集，從而識別僅靠傳統方法難以檢測到的治療機制和患者反應模式。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區正成為細胞和基因治療的重要中心，這主要得益於臨床研究活動的拓展、政府對生物技術的大力支持、基因組醫學的日益普及以及對先進治療產品生產投資的不斷成長。中國正積極進行細胞療法和基因編輯研究的臨床試驗，而日本已建立起再生醫學和先進治療產品的法律規範。韓國、澳洲、新加坡和印度正透過大學附屬醫院、國家級生物製造舉措以及支持創新的政策，不斷強化其臨床開發生態系統。然而，在醫療服務可近性、醫保報銷和基礎設施成熟度方面，各地區仍存在顯著差異。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體進行分析。

東協成員國包括新加坡、泰國、馬來西亞、印尼、越南和菲律賓，隨著生物醫學研究的拓展、醫院專科化和監管現代化進程的推進，東協在細胞和基因治療領域發揮日益重要的作用。新加坡是區域內先進生物製造、轉化研究和臨床試驗協調的中心，而泰國和馬來西亞則致力於提升再生醫學和專科醫療的能力。該地區的機會在於跨境臨床合作和醫療基礎設施的擴建，但成功實施的關鍵在於成本效益、監管協調、人力資源開發以及可靠的低溫運輸系統。

對不同國家主要細胞和基因治療市場的關鍵見解。

美國擁有最成熟的細胞和基因治療國家生態系統，其背後有廣泛的臨床試驗網路、專業的治療中心、完善的監管指導、基因組檢測基礎設施和先進的生物製造能力。加拿大透過幹細胞科學、癌症免疫療法研究和協調的轉化計畫做出貢獻，而墨西哥則透過其臨床研究能力、不斷拓展的腫瘤醫學以及與北美供應鏈的地理優勢，持續提升自身在該領域的影響接近性。巴西是拉丁美洲領先的細胞和基因治療中心，擁有強大的學術和醫療體系，並與公共研究機構和監管機構在先進療法方面日益密切的合作。

為細胞和基因治療行業的領導者提供的實用建議

產業領導者應優先考慮平台策略，在科學差異化、生產可行性、監管清晰度和市場準備度之間取得平衡。早期投資於可擴展的製程開發、可靠的分析表徵、功效檢測和可比性計劃，將有助於減少後期延誤，並促進與監管機構的順暢合作。對於細胞療法，應儘早實施自動化、封裝和數位化身分鏈系統。對於基因療法，載體生產率、組織標靶化、免疫抗原性控制和持久性證據仍應是研發的核心重點。

理解實證細胞和基因治療的調查方法

本執行摘要基於系統性的二手研究方法，利用公開可查且檢驗的資訊來源，包括監管指南、同行評審的科學文獻、臨床試驗註冊資訊、公共衛生機構文件、行業標準、政策文件和醫療保健系統研究途徑。本分析重點在於細胞和基因治療在科學、監管、生產、臨床應用、區域發展和可及性等方面的實際趨勢。

結論：細胞和基因療法具有擴充性，並且在實現基於證據的患者療效方面正在取得進展。

細胞和基因療法正進入一個更規範化的階段，突破性的科學成果必須與可擴展的生產、嚴謹的證據生成、監管的一致性以及公平的獲取途徑相輔相成。該領域正透過基因修飾免疫細胞、基因替代、體內遞送、基因組編輯、再生醫學平台和人工智慧驅動的開發工具不斷取得進展。然而，為了實現永續的影響，必須解決與生產一致性、物流、長期安全監測、治療設施容量、保險報銷和病患識別相關的營運挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 細胞與基因治療市場：依治療類型分類

  • 細胞療法
    • 幹細胞療法
      • 造血幹細胞療法
      • 間質幹細胞療法
    • T細胞療法
      • CAR-T細胞療法
      • 基於T細胞受體（TCR）
  • 基因治療
    • 體外基因治療
    • 體內基因治療

第8章 細胞與基因治療市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈

第9章 細胞與基因治療市場：依治療階段分類

  • 臨床前階段
  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 已通過核准的商業化治療

第10章 細胞與基因治療市場：依治療領域分類

  • 心血管系統
    • 鬱血性心臟衰竭
    • 缺血性心臟疾病
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 神經病變
    • 阿茲海默症
    • 亨丁頓舞蹈症
    • 多發性硬化症
    • 帕金森氏症
    • 脊髓損傷
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 淋巴瘤
    • 固體癌
  • 眼科

第11章 細胞與基因治療市場：依最終用戶分類

  • 學術研究機構
  • 醫院
    • 腫瘤中心
    • 移植中心
  • 專科診所
    • 基因治療診所
    • 細胞治療診所
  • 製藥公司

第12章 細胞與基因治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 細胞與基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 細胞與基因治療市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 日本
  • 印度
  • 法國
  • 加拿大
  • 澳洲
  • 義大利
  • 西班牙
  • 韓國
  • 俄羅斯
  • 巴西
  • 墨西哥

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • 4D Molecular Therapeutics, Inc.
  • Adaptimmune LLC
  • Amgen Inc.
  • Autolus Limited
  • Beam Therapeutics Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • CSL Behring LLC
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Krystal Biotech, Inc.
  • Mesoblast, Inc.
  • Novartis AG
  • Pfizer Inc.
  • REGENXBIO Inc.
  • Rocket Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • uniQure NV
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market is projected to grow by USD 71.38 billion at a CAGR of 20.39% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.47 billion
Estimated Year [2026] USD 22.98 billion
Forecast Year [2032] USD 71.38 billion
CAGR (%) 20.39%

Cell & Gene Therapy Executive Summary: Precision Medicine Moves Toward Durable Treatment Models

Cell and gene therapy is redefining modern medicine by shifting treatment models from chronic disease management toward potentially durable, mechanism-based interventions. The field spans autologous and allogeneic cell therapies, gene replacement, gene addition, gene editing, viral and non-viral vectors, ex vivo and in vivo delivery, and enabling technologies such as advanced bioprocessing, potency assays, cryopreservation, and digital quality systems. Clinically, the strongest momentum remains in oncology, hematology, rare genetic disorders, ophthalmology, neurology, immunology, and regenerative medicine, where therapies are designed to address underlying biological drivers rather than only symptoms.

Regulatory experience has expanded meaningfully across major jurisdictions, with agencies issuing guidance on chemistry, manufacturing, and controls, long-term follow-up, comparability, donor eligibility, vector safety, genome editing risk assessment, and real-world evidence. At the same time, commercialization remains complex because cell and gene therapy products often require specialized manufacturing, stringent cold chain logistics, patient-specific scheduling, qualified treatment centers, pharmacovigilance infrastructure, and novel reimbursement mechanisms. The sector's next phase is being shaped by scalable manufacturing, better analytical characterization, improved safety engineering, broader access models, and the integration of artificial intelligence across discovery, development, operations, and patient monitoring.

Transformative Shifts in the Cell & Gene Therapy Landscape

The cell and gene therapy landscape is undergoing transformative shifts as scientific innovation converges with manufacturing maturity, regulatory learning, and healthcare system adaptation. A major shift is the progression from first-generation autologous therapies toward more scalable approaches, including allogeneic cell platforms, next-generation immune cell engineering, in vivo gene delivery, base and prime editing, tissue-targeted vectors, and non-viral delivery systems. These advances are intended to reduce production complexity, improve treatment consistency, shorten vein-to-vein timelines, and expand therapeutic reach beyond highly specialized centers.

Manufacturing is also becoming a strategic differentiator. Closed-system processing, automation, digital batch records, modular cleanroom models, process analytical technologies, and improved release testing are being adopted to address variability and strengthen quality control. Supply chains are evolving around cryogenic storage, chain-of-identity and chain-of-custody systems, just-in-time logistics, and resilient sourcing of plasmids, viral vectors, media, reagents, and single-use components. Meanwhile, regulators are emphasizing robust comparability frameworks as developers optimize processes after early clinical success.

Commercialization models are changing as payers, providers, and policymakers evaluate value-based arrangements, outcomes tracking, staged payments, and national access pathways for high-complexity therapies. Treatment centers are investing in multidisciplinary capabilities that combine apheresis, cell processing coordination, intensive patient monitoring, genomic diagnostics, and long-term follow-up. These shifts indicate that competitive advantage will depend not only on clinical efficacy, but also on manufacturability, safety profile, treatment-site readiness, payer acceptance, and evidence generation over time.

Cumulative Impact of Artificial Intelligence on Cell & Gene Therapy

Artificial intelligence is having a cumulative impact across the cell and gene therapy value chain by improving decision-making in discovery, translational research, manufacturing, clinical operations, and post-treatment monitoring. In early-stage development, AI-enabled models support target identification, vector optimization, guide RNA design, protein engineering, cell phenotype prediction, and biomarker discovery. Machine learning can help analyze high-dimensional genomic, transcriptomic, proteomic, imaging, and single-cell datasets to identify therapeutic mechanisms and patient-response patterns that would be difficult to detect using conventional methods alone.

In manufacturing, AI is increasingly relevant for process control, anomaly detection, predictive maintenance, yield improvement, contamination risk reduction, and release-test optimization. Cell therapies are especially sensitive to biological variability, and AI-based analytics can support more consistent interpretation of critical quality attributes such as viability, potency, transduction efficiency, expansion dynamics, and phenotype stability. Digital twins and advanced statistical models are also being explored to reduce development cycles and improve process comparability.

In clinical and commercial settings, AI can strengthen patient identification by supporting genomic screening, electronic health record analysis, referral pathway optimization, and trial matching. It also has a role in pharmacovigilance through signal detection, adverse-event pattern recognition, and long-term outcomes monitoring. However, implementation requires validated algorithms, explainable models, compliant data governance, cybersecurity, bias mitigation, and alignment with evolving regulatory expectations for software-enabled decision support. The most practical near-term impact lies in augmenting expert workflows rather than replacing scientific, clinical, or regulatory judgment.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is becoming a major cell and gene therapy region due to expanding clinical research activity, strong government support for biotechnology, increasing genomic medicine adoption, and growing investment in advanced therapy manufacturing. China has built substantial activity in cell therapy trials and gene-editing research, while Japan has established regulatory pathways for regenerative medicine and advanced therapy products. South Korea, Australia, Singapore, and India are strengthening clinical development ecosystems through academic hospitals, national biomanufacturing initiatives, and supportive innovation policies, although access, reimbursement, and infrastructure maturity vary widely across the region.

North America remains one of the most developed regions for cell and gene therapy because of established regulatory pathways, advanced clinical trial networks, experienced treatment centers, strong venture and public research funding, and broad adoption of genomic diagnostics. The United States anchors regional activity through a mature ecosystem of academic medical centers, contract development and manufacturing capacity, specialized logistics providers, and regulatory guidance for advanced therapies. Canada contributes through stem cell research, cancer immunotherapy programs, and public-private translational infrastructure.

Latin America is gradually expanding its cell and gene therapy capabilities, led by Brazil and Mexico alongside emerging activity in Argentina, Chile, and Colombia. Regional progress is supported by growing oncology care capacity, academic research networks, and interest in regulatory harmonization, but access to high-complexity advanced therapies remains constrained by reimbursement limitations, uneven specialist infrastructure, and dependence on imported technologies. Local capacity-building in clinical trials, biobanking, quality systems, and regulatory science is expected to be central to sustainable adoption.

Europe has a highly structured advanced therapy environment supported by centralized regulatory assessment, strong academic research, hospital exemption frameworks, and established expertise in hematology, oncology, rare diseases, and regenerative medicine. Germany, France, the United Kingdom, Italy, Spain, the Netherlands, and the Nordic countries are active in clinical research and manufacturing infrastructure. The region's main challenges include reimbursement fragmentation, country-specific health technology assessment requirements, cross-border access complexity, and the need for scalable production models that meet rigorous quality standards.

The Middle East is building cell and gene therapy capacity through precision medicine initiatives, genomics programs, transplant centers, and specialized healthcare investments. GCC countries are particularly focused on rare disease diagnostics, oncology care, and advanced hospital infrastructure, supported by national strategies to diversify healthcare innovation. Adoption remains concentrated in leading tertiary centers, with long-term growth dependent on regulatory maturity, local talent development, biomanufacturing capabilities, and sustainable reimbursement frameworks.

Africa remains at an early stage in cell and gene therapy adoption, but the region has important long-term relevance due to genetic diversity, unmet medical needs, and opportunities for genomic medicine partnerships. South Africa has the most visible research and clinical infrastructure, while other countries are developing capabilities through academic collaborations, infectious disease research platforms, and biobanking initiatives. Key constraints include limited manufacturing infrastructure, affordability barriers, scarce specialized clinical capacity, and the need for regulatory strengthening. Ethical data governance, equitable access, and locally relevant clinical research will be essential to responsible development.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN is increasingly relevant to cell and gene therapy because member states such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are expanding biomedical research, hospital specialization, and regulatory modernization. Singapore functions as a regional hub for advanced biomanufacturing, translational research, and clinical trial coordination, while Thailand and Malaysia are building capabilities in regenerative medicine and specialty care. The region's opportunity lies in cross-border clinical collaboration and healthcare infrastructure expansion, but adoption will depend on affordability, harmonized regulation, workforce training, and reliable cold chain systems.

The GCC is positioning itself as a precision medicine and advanced therapy adopter through national genomics programs, tertiary hospital investment, and policies designed to localize high-value healthcare capabilities. Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman are increasing attention to rare diseases, inherited disorders, oncology, and transplant medicine. For cell and gene therapy, the GCC's strengths include advanced hospital infrastructure and strategic healthcare funding, while gaps remain in local manufacturing depth, specialized talent pipelines, regulatory harmonization, and long-term outcomes registries.

The European Union provides one of the world's most formalized frameworks for advanced therapy medicinal products, supporting centralized scientific evaluation, pharmacovigilance requirements, and quality standards. EU member states contribute strong academic research, public funding mechanisms, and clinical expertise, but patient access is shaped by national reimbursement decisions and health technology assessments. The EU's future competitiveness in cell and gene therapy will depend on accelerating clinical translation, improving manufacturing scalability, supporting hospital-based innovation responsibly, and aligning evidence expectations across member countries.

BRICS countries represent diverse but strategically important cell and gene therapy environments. China is highly active in clinical research and biotechnology scale-up, India is expanding affordable biomanufacturing and genomic medicine capabilities, Brazil has leading Latin American research infrastructure, Russia maintains scientific expertise in immunology and biotechnology, and South Africa contributes regional leadership in biomedical research. The group's combined relevance lies in large patient populations, public health needs, and cost-sensitive innovation, but regulatory consistency, reimbursement, manufacturing quality systems, and equitable access remain key priorities.

G7 countries collectively hold deep capabilities across advanced therapy research, regulatory science, clinical infrastructure, manufacturing technology, and payer assessment. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom have established or evolving pathways for advanced therapies, with strong academic and hospital networks supporting clinical translation. Their influence extends to global standards for evidence generation, long-term safety monitoring, manufacturing quality, and reimbursement innovation. Continued leadership will depend on reducing treatment bottlenecks, expanding qualified care networks, and improving affordability without weakening safety and efficacy standards.

NATO countries include many of the most mature cell and gene therapy ecosystems, especially across North America and Europe. Their relevance is not limited to defense alignment; it includes advanced biomedical research capacity, resilient supply chain planning, cybersecurity expectations for health data, and cross-border scientific collaboration. Cell and gene therapy development in NATO-aligned healthcare systems benefits from strong regulatory institutions and specialized clinical centers, while also facing complex reimbursement, data interoperability, and manufacturing resilience challenges. Secure, traceable, and redundant supply chains are becoming increasingly important for advanced therapy continuity.

Key Country Insights Across Leading Cell & Gene Therapy Markets

The United States is the most mature national ecosystem for cell and gene therapy, supported by extensive clinical trial networks, specialized treatment centers, regulatory guidance, genomic testing infrastructure, and advanced biomanufacturing capabilities. Canada contributes through stem cell science, cancer immunotherapy research, and coordinated translational programs, while Mexico is building relevance through clinical research capacity, oncology care expansion, and proximity to North American supply chains. Brazil is Latin America's leading cell and gene therapy environment, with strong academic medicine, public research institutions, and growing regulatory engagement around advanced therapies.

The United Kingdom remains influential through genomics-driven healthcare programs, academic clinical trial networks, and advanced therapy manufacturing initiatives. Germany is a European leader in biotechnology, hospital-based research, and industrial manufacturing quality, while France combines strong public research, rare disease expertise, and advanced therapy clinical development. Russia has scientific strengths in immunology, virology, and biotechnology, although international collaboration and access dynamics are influenced by geopolitical and regulatory factors. Italy and Spain are active in advanced therapy research, hematology, oncology, and hospital-based treatment delivery, with access shaped by national reimbursement and regional healthcare structures.

China has become one of the most active countries in cell therapy and gene-editing research, supported by large clinical research networks, domestic biotechnology investment, and policy attention to innovative medicines. India is gaining importance through cost-efficient biomanufacturing, expanding clinical research, and growing interest in genomic medicine, though affordability and infrastructure readiness remain central challenges. Japan has a distinctive regenerative medicine framework and a strong record in induced pluripotent stem cell research, alongside established pathways for advanced therapy evaluation. Australia supports cell and gene therapy through high-quality clinical trials, public research funding, and translational manufacturing programs. South Korea is advancing rapidly through biotechnology investment, hospital research networks, and government support for regenerative medicine and advanced biopharmaceuticals.

Actionable Recommendations for Cell & Gene Therapy Industry Leaders

Industry leaders should prioritize platform strategies that balance scientific differentiation with manufacturing feasibility, regulatory clarity, and access readiness. Early investment in scalable process development, robust analytical characterization, potency assays, and comparability planning can reduce late-stage delays and support smoother regulatory interactions. For cell therapies, automation, closed processing, and digital chain-of-identity systems should be embedded early. For gene therapies, vector productivity, tissue targeting, immunogenicity management, and durability evidence should remain central development priorities.

Organizations should also integrate access planning from the earliest stages of clinical development. This includes defining meaningful endpoints, generating evidence relevant to health technology assessment bodies, establishing long-term follow-up registries, and preparing outcomes-based reimbursement frameworks where appropriate. Clinical operations should focus on referral network development, treatment-center qualification, patient scheduling, apheresis coordination, and adverse-event management protocols.

Artificial intelligence should be adopted through validated, use-case-specific applications in discovery, manufacturing analytics, patient identification, and pharmacovigilance. Leaders should implement strong data governance, model validation, cybersecurity safeguards, and bias controls. Strategic partnerships with hospitals, academic centers, regulators, logistics providers, and manufacturing specialists can improve execution resilience. Above all, competitive advantage will come from aligning clinical promise with operational excellence, safety assurance, and sustainable patient access.

Research Methodology for Evidence-Backed Cell & Gene Therapy Insights

This executive summary is based on a structured secondary research approach using publicly available and verifiable sources, including regulatory guidance, peer-reviewed scientific literature, clinical trial registries, public health agency materials, industry standards, policy documents, and healthcare system publications. The analysis emphasizes factual trends in cell and gene therapy science, regulation, manufacturing, clinical translation, regional development, and access dynamics.

The methodology focuses on triangulating evidence across multiple source categories to reduce reliance on any single data point. Regulatory insights are interpreted from official agency frameworks and guidance documents related to advanced therapy medicinal products, biologics, gene therapy, genome editing, long-term follow-up, and manufacturing quality. Clinical and scientific insights are drawn from published research and trial activity patterns, while regional and country insights are informed by public innovation strategies, healthcare infrastructure developments, genomics initiatives, and translational medicine programs.

The scope intentionally excludes market sizing, market share calculations, revenue estimates, and forecasts. Instead, it evaluates qualitative and evidence-backed indicators such as regulatory maturity, clinical infrastructure, manufacturing readiness, technology adoption, reimbursement complexity, and access barriers. This approach supports strategic decision-making while maintaining compliance with verified, data-backed content requirements.

Conclusion: Cell & Gene Therapy Advances Toward Scalable, Evidence-Driven Patient Impact

Cell and gene therapy is entering a more disciplined phase in which breakthrough science must be matched by scalable manufacturing, rigorous evidence generation, regulatory alignment, and equitable access. The field continues to advance through engineered immune cells, gene replacement, in vivo delivery, genome editing, regenerative medicine platforms, and AI-enabled development tools. However, the path to sustainable impact depends on solving operational challenges around production consistency, logistics, long-term safety monitoring, treatment-center capacity, reimbursement, and patient identification.

Regional ecosystems are developing at different speeds, with North America, Europe, and parts of Asia-Pacific leading in regulatory and clinical maturity, while Latin America, the Middle East, and Africa focus on capacity-building and selective adoption. Group-level dynamics across ASEAN, GCC, the European Union, BRICS, G7, and NATO highlight the importance of policy coordination, infrastructure investment, and resilient supply chains. For industry leaders, the central opportunity is to build cell and gene therapy models that are clinically meaningful, operationally scalable, economically viable, and accessible to the patients most likely to benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell & Gene Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Cell Therapy
    • 7.2.1. Stem Cell Therapies
      • 7.2.1.1. Hematopoietic Stem Cell Therapies
      • 7.2.1.2. Mesenchymal Stem Cell Therapies
    • 7.2.2. T Cell Therapy
      • 7.2.2.1. CAR T Cell Therapy
      • 7.2.2.2. T Cell Receptor (TCR)-based
  • 7.3. Gene Therapy
    • 7.3.1. Ex Vivo Gene Therapy
    • 7.3.2. In Vivo Gene Therapy

8. Cell & Gene Therapy Market, by Administration Route

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous

9. Cell & Gene Therapy Market, by Therapy Stage

  • 9.1. Introduction
  • 9.2. Preclinical Stage
  • 9.3. Clinical Trials
    • 9.3.1. Phase I
    • 9.3.2. Phase II
    • 9.3.3. Phase III
  • 9.4. Approved Commercial Therapies

10. Cell & Gene Therapy Market, by Therapeutic Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular
    • 10.2.1. Congestive Heart Failure
    • 10.2.2. Ischemic Heart Disease
  • 10.3. Metabolic Disorders
    • 10.3.1. Diabetes
    • 10.3.2. Obesity
  • 10.4. Neurological Disorders
    • 10.4.1. Alzheimer's Disease
    • 10.4.2. Huntington's Disease
    • 10.4.3. Multiple Sclerosis
    • 10.4.4. Parkinson's Disease
    • 10.4.5. Spinal Cord Injuries
  • 10.5. Oncology
    • 10.5.1. Hematological Malignancies
    • 10.5.2. Lymphomas
    • 10.5.3. Solid Tumors
  • 10.6. Ophthalmology

11. Cell & Gene Therapy Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Hospitals
    • 11.3.1. Oncology Centers
    • 11.3.2. Transplant Centers
  • 11.4. Specialty Clinics
    • 11.4.1. Gene Therapy Clinics
    • 11.4.2. Cell Therapy Clinics
  • 11.5. Pharmaceutical Companies

12. Cell & Gene Therapy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cell & Gene Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cell & Gene Therapy Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. United Kingdom
  • 14.5. Japan
  • 14.6. India
  • 14.7. France
  • 14.8. Canada
  • 14.9. Australia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. South Korea
  • 14.13. Russia
  • 14.14. Brazil
  • 14.15. Mexico

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. 4D Molecular Therapeutics, Inc.
  • 16.2. Adaptimmune LLC
  • 16.3. Amgen Inc.
  • 16.4. Autolus Limited
  • 16.5. Beam Therapeutics Inc.
  • 16.6. BioMarin Pharmaceutical Inc.
  • 16.7. bluebird bio, Inc.
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. CRISPR Therapeutics AG
  • 16.10. CSL Behring LLC
  • 16.11. Editas Medicine, Inc.
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Fate Therapeutics, Inc.
  • 16.14. Gilead Sciences, Inc.
  • 16.15. Intellia Therapeutics, Inc.
  • 16.16. Iovance Biotherapeutics, Inc.
  • 16.17. Johnson & Johnson Services, Inc.
  • 16.18. Krystal Biotech, Inc.
  • 16.19. Mesoblast, Inc.
  • 16.20. Novartis AG
  • 16.21. Pfizer Inc.
  • 16.22. REGENXBIO Inc.
  • 16.23. Rocket Pharmaceuticals, Inc.
  • 16.24. Sangamo Therapeutics, Inc.
  • 16.25. Sarepta Therapeutics, Inc.
  • 16.26. Takeda Pharmaceutical Company Limited
  • 16.27. uniQure N.V.
  • 16.28. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOPOIETIC STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOPOIETIC STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOPOIETIC STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MESENCHYMAL STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MESENCHYMAL STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MESENCHYMAL STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL T CELL RECEPTOR (TCR)-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL T CELL RECEPTOR (TCR)-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL T CELL RECEPTOR (TCR)-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EX VIVO GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EX VIVO GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EX VIVO GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VIVO GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN VIVO GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VIVO GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL APPROVED COMMERCIAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL APPROVED COMMERCIAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL APPROVED COMMERCIAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPINAL CORD INJURIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPINAL CORD INJURIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SPINAL CORD INJURIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL LYMPHOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LYMPHOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LYMPHOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENE THERAPY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE THERAPY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENE THERAPY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 269. GCC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 309. G7 CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. G7 CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. G7 CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 313. G7 CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 316. G7 CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 317. G7 CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 320. G7 CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 321. G7 CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 322. G7 CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. G7 CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. G7 CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 325. G7 CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 326. NATO CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. NATO CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. NATO CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. NATO CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 330. NATO CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. NATO CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. NATO CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 333. NATO CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 334. NATO CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 335. NATO CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 336. NATO CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 337. NATO CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 338. NATO CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 339. NATO CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. NATO CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. NATO CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 342. NATO CELL & GENE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 343. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY THERAPY STAGE, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, 20